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PURPOSE. To determine the association of statins, five classes of antihypertensive medications,
and proton pump inhibitors with (1) primary open-angle glaucoma (POAG) progression and
(2) conversion of POAG suspects to POAG.
METHODS. We retrospectively investigated the records of a cohort with POAG cases and
suspects from the Groningen Longitudinal Glaucoma Study. To quantify visual field (VF)
deterioration in cases, we used the rate of progression of the mean deviation (MD). Suspects
were considered to have converted at the time point after which two consecutive VF tests for
at least one eye were abnormal (glaucoma hemifield test outside normal limits). Progression
and conversion were analyzed with quantile and logistic regression, respectively, with the
systemic medications as predictors, controlling for age, sex, body mass index, pretreatment
IOP, corneal thickness, and baseline MD. The multivariable models were built with and
without IOP intervention.
RESULTS. No systemic medications were associated with POAG progression in the final IOP/
treatment-adjusted or unadjusted model. However, angiotensin II receptor blockers (ARBs)
appeared to slow progression in older patients (b ¼ 0.014, P ¼ 0.0001). Angiotensin-
converting enzyme inhibitors (ACEIs) were significantly associated with a decrease in POAG
suspect conversion in both the IOP/treatment-adjusted and -unadjusted model (odds ratio
[OR] 0.23, 95% confidence interval [CI] 0.07–0.79, P ¼ 0.012; OR¼0.24, 95% CI 0.07–0.78, P
¼ 0.021, respectively), as were ARBs (OR 0.12, 95% CI 0.01–0.98, P ¼ 0.014; OR 0.11, 95% CI
0.01–0.87, P ¼ 0.005, respectively).
CONCLUSIONS. No overall association of VF progression with systemic medication was found;
ARBs delayed progression in older patients. ACEIs and ARBs were associated with lower risk
of suspect conversion. The pathophysiology of this relationship is to be disentangled.
Keywords: glaucoma, ocular hypertension, antihypertensives, statins, proton pump inhibitors
Glaucoma is a chronic and progressive eye diseasecharacterized by cupping of the optic disc, thinning of
the retinal nerve fiber layer, loss of retinal ganglion cells
(RGCs), and loss of visual function.1,2 A high IOP is an
important risk factor for glaucoma and IOP-lowering medica-
tions, laser, or surgery are currently the only available options
to delay, but not inhibit, glaucomatous progression.3,4 Howev-
er, not every person with ocular hypertension will convert to
the disease, and glaucoma also may develop in those with an
apparently normal IOP.5 These observations imply that other
risk factors exist that are not being addressed in current
treatment decisions.
Several other factors may contribute to the development and
progression of the disease, including systemic medications used
to treat other pathologies. Specifically, a protective role of
statins, possibly unrelated to their cholesterol-lowering effect,
has been reported in primary open-angle glaucoma (POAG).6–9
Moreover, numerous studies have examined the effect of
antihypertensive (AH) medication on glaucoma, because the
disease is believed to contain a vascular component.10–12 This
suggests that drugs able to modify vascular events could pertain
to the outcome of glaucoma. In this regard, proton pump
inhibitors (PPIs), a medication class used to lower the levels of
stomach acid in gastric and esophageal pathologies, could
influence unfavorably the course of the disease because of their
documented inhibition of nitric oxide (NO) production.13 To
make it even more complicated, these drugs could simulta-
neously have a beneficial effect because they create an
unfavorable gastric environment for Helicobacter pylori, a
bacterium for which an association with increased risk for
POAG has been suggested.14
However, the results of studies examining the role of
statins and AH medication in POAG are conflicting.15,16 A
neuroprotective property of statins as well as of certain AH
medications has been suggested, but not all studies confirm
such an effect.17,18 Even from a pathophysiological perspec-
tive, although hypertension has been suggested as a risk
factor for glaucoma, aggressive treatment with blood pressure
(BP) medication also could result in ischemic damage to the
RGCs mediated by a low diastolic BP.19 In addition, to the best
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of our knowledge, there currently exists only scarce evidence
addressing a potential effect of PPIs on POAG development.
Last, some study designs in the literature incorporate a loose
definition of POAG (e.g., prescription of glaucoma medica-
tion) based on national registries or insurance claim data.11,16
As a result, it is impossible to differentiate the impact of
systemic medication on glaucoma suspects from the corre-
sponding impact on those with a glaucoma diagnosis.
Therefore, the aim of this study was to determine the
association of statins, five main classes of AH medication, and
PPIs with (1) POAG progression and (2) conversion of POAG
suspects to a POAG diagnosis. For this purpose, we retrospec-
tively looked into the information of the Groningen Longitu-
dinal Glaucoma Study (GLGS) to determine exposure to the
aforementioned systemic medications in a cohort of POAG
patients and POAG suspects.
METHODS
Study Population
Patients were selected from the GLGS database. The GLGS
began in 2000 and was originally a prospective, observa-
tional cohort study conducted in the clinical setting of the
University Medical Center Groningen (UMCG), comprising
both glaucoma patients and glaucoma suspects (predomi-
nantly Caucasians). In 2000, the UMCG served both as an
academic and as a community hospital; most patients in the
current study should be considered community hospital
patients. The objectives and methods of the GLGS have
been previously described.20,21 After the onset of the
original GLGS, we continued adding newly diagnosed
glaucoma patients, making the GLGS a dynamic population.
From those patients who visited the clinic in 2015, we
recorded their current and past systemic medications, and
height and weight. This is the subset used in the current
study. For the glaucoma patients, we associated the rate of
progression (ROP; defined below) with systemic medica-
tion use, making the study design a retrospective follow-up
study. For glaucoma suspects, we compared systemic
medication use between those who converted to glaucoma
and those who did not, making the study design a case-
control study. The study protocol was approved by the
ethics board of the UMCG and followed the tenets of the
Declaration of Helsinki. All patients provided written
informed consent.
To be eligible, subjects had to be followed with standard
automated perimetry (see next subsection). Those with
pseudoexfoliative or pigment dispersion glaucoma or a history
of angle closure or secondary glaucoma were excluded
(leaving POAG and POAG suspects). For being a glaucoma
patient, glaucomatous visual field (VF) loss had to be present at
baseline in at least one eye.20 For glaucomatous baseline VF
loss, two consecutive tests had to be abnormal (see next
subsection) in at least one eye. Defects had to be compatible
with glaucoma and without any other explanation. A VF test
before the two baseline tests was discarded to reduce the
influence of learning. Thus, at least three tests had to be
performed at baseline before glaucomatous VF loss could be
diagnosed. Glaucoma suspects were those who had an intact
VF when entering the study and were followed in our
outpatient department because of ocular hypertension (IOP
above 20 mm Hg on at least two separate visits), a positive
family history of glaucoma (glaucoma reported in father,
mother, brother, or sister), or a suspected optic disc (cup-to-
disk ratio above 0.6), or combinations thereof.22
Perimetry, Progression, and Conversion
Perimetry was performed using the Humphrey Field Analyzer
(Carl Zeiss, Jena, Germany) 30–2 Swedish interactive threshold
algorithm fast strategy with 30–2 grid. An abnormal test result
was defined as a glaucoma hemifield test ‘‘outside normal
limits.’’ Test results were included only if they were reliable; a
test result was considered unreliable if false positives exceeded
10% or if both false negatives and fixation losses exceeded 10%
and 20%, respectively. We pooled false negatives and fixation
losses because they were reported to have a much smaller
influence on the mean deviation (MD) and the false negatives,
especially, are not informative in glaucoma.23,24
In glaucoma patients, the ROP was calculated as the slope
of the MD over time, after a minimum of 5 years of perimetric
follow-up.25 For the conversion analysis, subjects who were
glaucoma suspects were considered to have converted to a
glaucoma diagnosis at the time point after which all
subsequent VF tests (at least two) for at least one eye were
abnormal.
Risk Factors
The possible risk factors for glaucoma progression that were
included in this study were age at baseline, sex, body mass
index (BMI), highest pretreatment IOP, central corneal
thickness (CCT), baseline MD (dichotomized above and below
the median of9.4 dB),26 mean IOP during follow-up, surgery
for glaucoma (yes/no), number of glaucoma medications, and
systemic medications. Systemic medications included were
statins, diuretics, angiotensin II receptor blockers (ARBs),
angiotensin-converting enzyme inhibitors (ACEIs), calcium
channel blockers (CCBs), beta blockers, and PPIs. For the
number of glaucoma medications, topical and oral were
included, and if the patient underwent laser treatment, this
was considered as an additional medication.27
Systemic Medication Exposure Ascertainment
To verify systemic medication exposure, the complete medical
file of each patient was examined, in combination with a semi-
structured interview that took place in 2015 (at or toward the
end of the follow-up). An interviewer (blinded to the study
question and taking no other part in the study procedures)
asked each participant to list his or her current medications,
guiding them with additional questions, such as: ‘‘What
medications are you currently taking for high blood pressure/
high cholesterol/your heart/your stomach?’’ To ascertain prior
or subsequent use of the reported or other relevant
medications, we recorded all medication listings until the
end of the patient’s follow-up from the patient’s hospital file,
which included letters to his or her primary care doctors
detailing prescribed medications. We defined the ‘oldest
recorded exposure date’ as the very first date a drug appeared
in this listing (or mentioned in the interview), while being
absent from all listings of previous reports. We used this date
(1) to approximate the duration of systemic medication use
during follow-up for the progression analysis and (2) to
ascertain that systemic medication exposure occurred before
the conversion date in the conversion analysis.
Data Analysis
For the progression analysis, only one eye per patient was
included. If a patient met the inclusion criteria with both eyes,
a randomly chosen eye was included. Conversion was based on
a by-patient basis: those who converted with at least one eye
were considered to have converted; for analysis, the first
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converted eye was used and if no conversion took place, a
random eye was chosen. The patient characteristics were
described with mean and SD for normally distributed variables.
For variables with a skewed distribution, we used median and
interquartile range (IQR) instead. In the multivariable analysis
(see below), missing data for CCT (2 cases) and BMI (3 cases)
were imputed from the median value. There were no other
missing values for any other risk factor.
Because of the non-normality of the ROP distribution,
quantile regression was performed using a saturated model
with ROP as the outcome variable and all predictor variables
included. The least significant variable was then removed, and
the models with and without the least significant variable were
compared using the Akaike information criterion (AIC). If the
model without the concerning variable was the better fit for
the data, the same process was repeated for the next least
significant variable, and this process was continued until we
reached a minimal model. Coefficients and P values were
reported. The saturated model for the ROP regression can be
found in the supplementary material (Supplementary Table
S1).
Conversion of glaucoma suspects to a glaucoma diagnosis
was analyzed using a logistic regression model. The saturated
model included all the predictor variables included above,
except for glaucoma surgery and baseline MD, which would
both be irrelevant for those not yet diagnosed with glaucoma.
Mean IOP during follow-up was calculated either until the
point at which the patient converted, or for the entire follow-
up duration if the patient never converted. Again using the
AIC, covariates were removed and a minimal model was
created. Odds ratios (ORs) with 95% confidence intervals (CIs)
and P values were reported. The saturated model for the
conversion logistic regression model can be found in the
supplementary material (Supplementary Table S2).
All analyses were performed using R (version 3.3.3; R
Foundation for Statistical Computing, Vienna, Austria). A P
value of 0.05 or less was considered statistically significant.
According to the AIC, inclusion in the final model implies P <
0.16.
RESULTS
We included 250 patients in the ROP analysis and 112
glaucoma suspects for the conversion analysis. Of the 112
glaucoma suspects, 21 were included because of ocular
hypertension, 4 because of a positive family history of
glaucoma, 6 because of a suspected optic disc, and 81 because
of combinations thereof. Table 1 shows the characteristics of
the study population.
Median follow-up duration of the glaucoma patients was 12
years; median ROP 0.27 dB per year. Table 2 depicts the
univariable quantile regression analysis with median ROP as
the dependent variable. Older age, lower BMI, lower IOP
before treatment, and a higher number of glaucoma medica-
tions were significantly associated with faster progression.
Table 3 shows the final multivariable model for median ROP,
along with a model built without the variables that account for




Number of patients 250 53 59
Age at baseline, y; mean 6 SD 61.8 6 9.9 58.3 6 10.0 55.4 6 11.3
Sex, % female 46.0 56.6 54.2
BMI, kg/m2; mean 6 SD 26.2 6 4.2 25.6 6 3.8 27.2 6 4.5
IOP before treatment, mm Hg; median (IQR) 26.0 (22.0 to 31.0) 26.0 (23.0 to 30.0) 29.0 (24.0 to 32.0)
CCT, lm; median (IQR) 537.0 (512.5 to 566.0) 543.0 (519.0 to 558.0) 551.0 (539.5 to 576.0)
VF MD at baseline, dB; median (IQR) 9.4 (15.6 to 5.1) 1.1 (3.9 to 0.0) 0.8 (1.8 to 0.2)
Follow-up duration, y; median (IQR) 12.0 (9.0 to 15.0) 7.0 (4.0 to 12.0) 16.0 (13.0 to 18.0)
Mean IOP during follow-up, mm Hg; median (IQR) 13.2 (11.3 to 15.5) 15.5 (13.9 to 17.3) 17.1 (14.6 to 18.2)
ROP, dB/y; median (IQR) 0.27 (0.55 to 0.08) NA NA
Statins, % (n) 37.2 (93) 15.1 (8) 40.7 (24)
Statin duration, percentage of follow-up years; median (IQR) 45.6 (25.3 to 82.5) NA NA
Diuretics, % (n) 27.6 (69) 9.4 (5) 33.9 (20)
ARBs, % (n) 15.2 (38) 1.9 (1) 15.2 (9)
ACE inhibitors, % (n) 24.8 (62) 7.5 (4) 25.4 (15)
CCBs, % (n) 19.2 (48) 11.3 (6) 20.3 (12)
Beta blockers, % (n) 27.2 (68) 18.8 (10) 30.5 (18)
AH duration, percentage of follow-up y; median (IQR) 50.0 (27.3 to 100.0) NA NA
PPIs, % (n) 33.2 (83) 22.6 (12) 32.2 (19)
PPI duration, percentage of follow-up y; median (IQR) 44.4 (25.8 to 90.4) NA NA
NA, not applicable; VF MD, standard automated perimetry mean deviation.
TABLE 2. Univariable Quantile Regression Analysis for Glaucoma
Patients With Median ROP as Dependent Variable
Coefficient P Value
Age, y 0.006 0.003
Sex, female 0.080 0.15
BMI, kg/m2 0.010 0.050
IOP before treatment, mm Hg 0.005 0.008
CCT, lm 0.0002 0.76
VF MD at baseline, dB 0.000 1.0
Mean IOP during follow-up, mm Hg 0.005 0.52
Glaucoma surgery, 0 ¼ No 0.040 0.44




ACE inhibitors 0.060 0.23
CCBs 0.080 0.31
Beta blockers 0.080 0.16
PPIs 0.010 0.86
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intervention by the treating ophthalmologist (by excluding
mean IOP during follow-up, number of glaucoma medications,
and glaucoma surgery from the saturated model) to account for
any systemic medication-mediated IOP changes. In both final
models, older age and male sex were significantly associated
with faster progression. Specifically, for each 10 years of age,
the median ROP was 0.07 dB per year faster (0.06 dB per year
for the model excluding intervention). Statins and ARBs
remained in the model but were not significantly associated
with ROP.
For these two systemic medications, we completed a
secondary dose-response relationship analysis in which we
created categories based on duration of medication use,
defined as follows: no use, duration of use below the median,
and duration of use above the median. Compared with
nonusers of statins, there was a trend toward faster progression
with prolonged statin use (6 years or less, b¼0.083, P¼0.06;
more than 6 years, b¼0.130, P¼ 0.009). There was no dose-
response relationship found for ARBs.
We also repeated the analysis using a variable with the
cumulative number of AHs (in place of the different classes) as
a marker for the severity of hypertension, but this variable was
the first to leave the model, suggesting the number of AHs was
not associated with progression.
Interactions between the two systemic medications remain-
ing in the final model (ARBs and statins) and both pretreatment
IOP and age also were investigated, with a Bonferroni-adjusted
significance cutoff of P ¼ 0.0125. The only significant
interaction effect on ROP was between ARBs and age (b ¼
0.014, P ¼ 0.0001). For each additional 10 years of age, ARB
takers had a median ROP that was 0.14 dB per year slower than
non–ARB takers. In addition, tests for collinearity between
systemic medications revealed only a moderate collinear
relationship between beta blockers and ACEIs (phi ¼ 0.42, P
< 0.001), all other phi coefficients were similar or lower.
Of the 112 glaucoma suspects, 53 converted during follow-
up. The median follow-up duration until conversion was 7
years for those who converted; those who did not convert
were followed for a median of 16 years. The survival curve is
displayed in the Figure. From this curve, it can be predicted
that it will take 15 years for 50% of the suspects to convert.
Tables 4 and 5 present the univariable and final multivariable
logistic regression models, respectively, for glaucoma suspect
conversion. In the univariable analysis, a higher BMI, a higher
number of glaucoma medications, and the use of statins,
diuretics, ARBs, and ACEI were associated with a significant
decrease in conversion. Again, multivariable models were built
with and without mean IOP during follow-up and number of
glaucoma medications. In the final model, a higher number of
glaucoma medications and the use of ARBs and ACEI were
associated with a significant decrease in conversion to a
glaucoma diagnosis. Even in the final model without mean IOP
and IOP treatment, the rate of conversion of suspects on ARBs
FIGURE. Survival curve for the glaucoma suspect population. Conver-
sion to POAG is defined as the time point after which all subsequent VF
tests (at least two) for at least one eye were abnormal.
TABLE 4. Univariable Analysis With Glaucoma Suspect Conversion as
Dependent Variable
OR (95% CI) P Value
Age, y 1.03 (0.99–1.06) 0.14
Sex, female 1.1 (0.52–2.32) 0.80
BMI, kg/m2 0.91 (0.83–1.00) 0.043
IOP before treatment, mm Hg 0.98 (0.94–1.03) 0.44
CCT, lm 0.99 (0.98–1.00) 0.058
Mean IOP during follow-up, mm Hg 0.90 (0.80–1.01) 0.078
Number of glaucoma medications 0.53 (0.34–0.85) 0.004
Statins 0.26 (0.1–0.65) 0.002
Diuretics 0.20 (0.07–0.59) 0.001
ARBs 0.11 (0.01–0.87) 0.008
ACE inhibitors 0.24 (0.07–0.78) 0.009
CCBs 0.50 (0.17–1.44) 0.19
Beta blockers 0.53 (0.22–1.28) 0.15
PPIs 0.62 (0.26–1.43) 0.26






OR (95% CI) P Value OR (95% CI) P Value
Age, y NA NA 1.03 (0.99–1.07) 0.14
BMI, kg/m2 NA NA 0.93 (0.83–1.07) 0.15




0.59 (0.37–0.94) 0.025 NA NA
ARBs 0.12 (0.01–0.98) 0.014 0.11 (0.01–0.87) 0.005
ACE inhibitors 0.23 (0.07–0.79) 0.012 0.24 (0.07–0.78) 0.021






Coefficient P Value Coefficient P Value
Age, y 0.007 0.001 0.006 0.010
Sex, female 0.122 0.018 0.128 0.004
BMI, kg/m2 0.010 0.032 0.006 0.14
IOP before treatment,
mm Hg
0.004 0.12 0.004 0.077
CCT, lm 0.0008 0.14 0.0007 0.16
Number of glaucoma
medications
0.036 0.056 NA NA
Statins 0.083 0.086 NA NA
ARBs 0.089 0.097 NA NA
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and ACEIs was 89% and 76% lower, respectively, than those not
taking the drugs, suggesting the possible protective association
is not mediated by IOP. Tests for collinearity between systemic
medications revealed a moderate collinear relationship be-
tween beta blockers and CCBs (phi ¼ 0.53, P < 0.001), all
other phi coefficients were similar or lower.
DISCUSSION
No systemic medications were associated with POAG progres-
sion in the final IOP-intervention adjusted or unadjusted
model; statins and ARBs remained in the final IOP-intervention
adjusted model without reaching significance, but an interac-
tion term revealed a significantly slower progression associated
with ARBs for older ages. ACEIs and ARBs were significantly
associated with a decrease in POAG suspect conversion in the
final model, regardless of IOP-intervention adjustment.
Regarding the effect of statins on POAG progression, other
studies have given varying results. Iskedjian et al.12 reported no
significant differences in the need for adjunct topical IOP-
lowering medications between statin users and nonusers.
Leung et al.8 found that significantly more nonprogressors
were using statins. In contrast to our study, their study
concerned only normal tension glaucoma (NTG) subjects (256
subjects followed for 3 years; 31 taking statins). An interaction
term between statin use and pretreatment IOP added to our
model did not uncover a significant association, suggesting that
statins do not have a selective association with NTG in our
study population. De Castro et al.28 assessed progression with
structural parameters and reported that statin users, albeit only
those not receiving aspirin treatment simultaneously, had
lower progression rates (n¼ 76; smallest group n¼ 12; follow-
up duration: 5.5 years). This observation suggests that early
structural changes might be more sensitive to the effect of
statins compared with VF parameters, but a study assessing
both structure and function would be needed to clarify this
hypothesis. McCann et al.15 could not perform a meta-analysis
on these studies because the definitions of glaucoma differed.
Last, a propensity score analysis by Whigham et al.6 reported
that a history of statin use resulted in slower VF progression
(847 subjects followed for 3.5 years; 629 taking statins).
However, their propensity score was limited to age, sex,
baseline glaucomatous severity, and systemic medical condi-
tions; hence, it did not include some important variables
present in our analysis, especially the variables related to IOP.
Notably, in our study, the relevant ROP coefficient for the IOP-
intervention adjusted model suggests a faster progression
(0.083 dB per year for statin users compared with nonusers),
but this result did not reach significance (P ¼ 0.086). Our
secondary dose-response analysis suggested faster progression
for POAG patients using statins for more than 6 years (0.130
dB per year compared with nonusers, P ¼ 0.009), but
according to a recent publication this is more likely a result
of higher serum cholesterol.29 All these studies, including ours,
were observational studies; that is, the statins were not
prescribed as part of a randomized controlled trial (RCT).
With regard to statin use and POAG incidence, most
observational studies, but not all, agree that short-term statin
use (2 years or less) does not significantly affect the
risk.7,16,30–33 Among them, Stein et al.7 also examined the
conversion of glaucoma suspects (n ¼ 49.628) within a
retrospective longitudinal cohort design. They found that
POAG suspects who used statins for 1 or 2 years had a smaller
hazard for conversion (hazard ratio [HR] 0.907, 95% CI 0.846–
0.973), but not for the need for glaucoma surgery.7 It is
possible, of course, that any beneficial effect is only a result of
longer exposure to the medication.7,30,32 Interestingly, a large
observational prospective study by Talwar et al.9 (25,420
subjects; 15,898 taking statins) showed reduced POAG
incident risk after 2 years of statin use (HR 0.79, 95% CI
0.66–0.96), independent of the cholesterol-lowering effect,
dosage, and statin type. It has been suggested that this effect
may be mediated by neuroprotective mechanisms.17,34,35
Albeit significant in these studies with very large sample sizes,
the effect sizes were actually small. This illustrates that a visible
effect size in large samples does not immediately imply clinical
relevance. Notably, in the univariate analysis of our study,
statins are shown to be associated (after Bonferroni correction)
with a reduced odds ratio for suspect conversion (OR 0.26,
95% CI 0.1–0.65, P[adjusted] ¼ 0.014); however, the multivar-
iate model reveals that this association is mediated by
concomitant use of AH medications.
A recent observational study from insurance claim data
suggested a causal, protective effect of AH medication,
especially those in the renin-angiotensin category, with respect
to incident glaucoma.11 Hirooka et al.36 reported a similar
finding in an NTG sample treated with ACEIs, whereas Yang et
al.18 found a neuroprotective effect of ARBs in a rat model. The
authors hypothesized that the decrease in angiotensin II levels
reduces the activity of the NADPH-dependent oxidase com-
plex, thus reducing oxidative stress and the subsequent RGC
apoptosis. They also discussed that the increase in plasma
bradykinin caused by the ACEIs offers extra possibilities:
improved blood flow through activation of the L-arginine NO
pathway, or protection from glutamate-induced neurotoxicity.
In our study, ACEIs and ARBs were significantly associated with
lower odds of suspects converting to POAG, which is in
agreement with these results. In addition, the highly significant
interaction term between age and ARBs in our progression
analysis suggests that the older the glaucomatous patient, the
more they could benefit from an ARB, as far as their
glaucomatous progression is concerned.
The effects of other AH medications are less clear. Beta
blockers have been associated with decreased POAG incidence
in some studies, whereas the opposite has been reported for
CCBs and, sometimes, even ARBs.16,37,38 Diuretics were
associated with increased conversion risk of ocular hyperten-
sives in the European Glaucoma Prevention Study and
increased risk of POAG in other studies.31,38,39 A protective
effect of the cumulative number of AH drugs was reported by
Horwitz et al.11; in addition, Iskedjian et al.12 showed that the
use of AH medication reduced the need for adjunct topical IOP-
lowering medication. Overall, these results suggest that AH
medication classes might contribute differently to the course of
glaucoma; this points toward the fact that pathways other than
the BP-lowering effect could be involved.40,41 Protection could
be mediated by an IOP-lowering effect42–46; additional
neuroprotective mechanisms have been attributed to medica-
tion in the renin-angiotensin category, as discussed in the
previous paragraph.47–49
There are several reasons for these conflicting results.
POAG treatment is a dynamic procedure in which the
clinician’s decisions interfere with the true (untreated) disease
progression. Therefore, explanatory variables, such as mean
IOP during follow-up or number of glaucoma medications,
could mediate or antagonize effects observed in other studies.
Furthermore, a threshold effect could exist for certain AH
drugs, or a ceiling effect with no further increase in risk for
glaucomatous damage after this ceiling has been reached,
hampering consistent dose-response findings.16,37 Last, it is
possible that AH treatment is beneficial only when started
timely and harmful if started after many years of untreated
hypertension. This, however, is impossible to address in an
observational study with limited information regarding the
time course of BP and its treatment. Interestingly, overtreat-
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ment of hypertension leading to hypotension has been
reported as a risk factor for glaucoma.19,50 Noticeably, data
extracted from a large cohort study (LifeLines Biobank) reveal
that aggressive AH treatment is hardly the case in our region,
the northern Netherlands.51 Indeed, average (SD) systolic BP/
diastolic BP values for users and nonusers of AH medication
are, within Lifelines, 135(17)/79(10) and 128(15)/76(9),
respectively.
PPIs appear to both mitigate and worsen glaucoma. In a
study investigating systemic medication use and glaucoma in
insurance claims data,16 it was found that esomeprazole (a
PPI), reduced the risk of POAG. This finding was of borderline
significance, but the authors hypothesized that it could be due
to a reduction in Helicobacter pylori rates, and therefore
reduced risk of POAG.14,52 However, PPIs also can decrease
production of NO, a vasodilator that plays a role in IOP
regulation. POAG patients may already have a genetic and
dietary susceptibility to reduced NO bioavailability.53 In this
regard, PPIs may be beneficial to those who do not have
alterations in genes responsible for NO production, and
harmful to those who do.
This study is limited by its retrospective design and its
relatively small sample size. For medication ascertainment, our
primary metric was ‘‘any use during follow-up’’ (a commonly
used metric in pharmacoepidemiology), but we added duration
of use information for the progression analysis and temporal
information for the conversion analysis (by ascertaining that
systemic medication exposure occurred before the conversion
date). Obviously, this metric is still limited by the absence of
dosage information. Furthermore, we did not have BP
measurements, and for this reason we could not perform a
mediation analysis for BP. Instead, we used the number of BP
medications as a crude proxy of disease severity. In spite of
that, it is true that monotherapy is the traditional initial therapy
for hypertension and subsequent medications are added
depending on BP target and disease severity. The absence of
BP measurements also did not allow us to examine overtreat-
ment of hypertension, a situation that could lead to under-
perfusion of the RGCs and, hence, mask any protective effects.
Nevertheless, our positive findings remain somewhat robust to
this limitation, as they all lie on the protective side, whereas
overtreatment is expected to have a negative effect on
glaucoma progression or conversion. In addition, our popula-
tion was predominantly Caucasian, so our results cannot be
safely generalized, especially because of differential responses
to cardiovascular agents among patients of different genetic
ancestries. Last, our population’s median age leans toward the
younger side with regard to glaucoma populations, a limitation
that we tried to address by assessing the interactions between
systemic medication exposure and age in the models.
The main strength of this study is the long follow-up
duration of the population. Furthermore, POAG patients and
suspects were defined according to strict criteria, rather than
being based on data from national registry or insurance claims.
This ensures that the two groups are not cross-contaminated
and that no other type of glaucoma is present in the dataset.
Moreover, a novelty of this study is controlling the analysis for
glaucoma medications, the surgical profile of each participant
(operated/not operated), and mean IOP during follow-up. We
believe that this reflects reality better, as it simulates the
dynamic context of clinicians intervening in the process by
trying to slow the glaucomatous progression.
Our study suggests that, within a glaucoma or glaucoma
suspect population with regular follow-ups and well-controlled
IOP, there exists some extra benefit added by BP medication,
but its clinical relevance is unclear. A better study design and a
larger sample size are both needed to strengthen these
findings. Also interesting from a clinical perspective, a high
pretreatment IOP is paradoxically almost beneficial on ROP
(stays in the final model, but does not reach significance),
whereas most studies show the opposite effect or no effect
whatsoever.26,54,55 This finding indicates that, in this popula-
tion, the alarm of a higher baseline IOP could have resulted in
early diagnosis and efficient, possibly more aggressive,
treatment. As such, it is a marker of clinician’s responsiveness
that is visible due to the observational study design rather than
a disease property.
In this study, approximately 47% of glaucoma suspects
converted to glaucoma within a median follow-up of 16 years.
According to the Ocular Hypertension Treatment Study
(OHTS), the expected percentage of converted cases within
5 years is 5% to 10%, so, assuming a linear relation, fewer than
30% of our suspects should have converted.56 A possible
explanation for this discrepancy could be because a healthy
optic disc at baseline was additionally required in the OHTS;
we also included suspects based on a suspected optic disc (47
of 112). In addition, a positive family history was present in
44% of the participants in OHTS, to be compared with 58% in
our study.57 Together, these differences suggest that our
participants were already ‘‘further down the line’’ at baseline.
Also, the OHTS used a stricter criterion for conversion (three
consecutive abnormal last VF tests, rather than two); however,
all of the converted suspects in our study actually had three
consecutive abnormal last VF tests, as well. It also must be
noted that 6 of 59 nonconverted suspects in our study had
(only) one abnormal last VF, but this was not enough to classify
them as ‘‘converted,’’ because most of these cases are
expected to yield a healthy VF on their next visit.58 Our
converters fulfilled the functional criteria of the OHTS, but we
did not have data to also include the structural criteria of the
OHTS. As such, the difference in conversion rate between both
studies is larger than reported above.
In conclusion, we found no overall significant association of
glaucomatous VF progression with systemic medication
exposure, but ARBs appeared to significantly delay progression
in older patients. ACEIs and ARBs were significantly associated
with a lower risk of suspect conversion to POAG. Because this
study was limited by its design, further investigations, ideally
RCTs, are needed to examine these relationships; should they
be proven true, their exact pathophysiology is yet to be
disentangled.
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